RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
Promoter methylation controls the intratumoral heterogeneity of Cancer/Testis antigens expression in human cutaneous melanoma: Immunotherapeutic implications of epigenetic drugs
2006-01-01 Fratta, E; Sigalotti, L; Coral, S; Covre, A; Nicolay, H; Pezzani, L; Cortini, E; Colizzi, F; Fonsatti, E; Altomonte, M; Maio, M
Quantitative analysis of the expression of HLA-class I, -A, -A2 antigens beta(2)mu expressed on melanoma cells and autologous PBMC
1996-01-01 Gasparollo, A; Marcon, G; Cattarossi, I; Cattelan, A; Altomonte, M; Maio, M
Safety and efficacy of ipilimumab 10 mg/kg among patients with advanced melanoma from Italy enrolled in a European compassionate use program (EAP)
2012-01-01 Maio, M; Queirolo, P; Testori, A; Altomonte, M; Maur, M; Bajetta, E; Ascierto, Pa; Chiarion Sileni, V; DI GIACOMO, ANNA MARIA; Ridolfi, R
Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study.
2019-01-01 DI GIACOMO, ANNA MARIA; Covre, Alessia; Finotello, Francesca; Rieder, Dietmar; Sigalotti, Luca; Giannarelli, Diana; Petitprez, Florent; Lacroix, Laetitia; Cutaia, Ornella; Fazio, Carolina; Coral, Sandra; Anichini, Andrea; Bock, Christoph; Lowder, James N.; Azab, Mohammad; Fridman, Wolf-Herman; Sautes-Fridman, Catherine; Trajanoski, Zlatko; Maio, Michele
Specific cellular immune responses against NY-ESO-1 are associated with favorable survival of stage IV melanoma patients
2011-01-01 Weide, B; Zelba, H; Derhovanessian, E; Pflugfelder, A; Schadendorf, D; de Vries, J; Maio, M; Garbe, C; Pawelec, G
Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma
2013-01-01 Maio, M; Bondarenko, I; Robert, C; Thomas, L; Garbe, C; Testori, A; Lu, H; Chin, K; Wolchok, J
THE ITALIAN EXPERIENCE ON THE FEASIBILITY AND SAFETY OF IPILIMUMAB THERAPY IN PRETREATED METASTATIC MELANOMA PATIENTS
2009-01-01 Altomonte, M; Queirolo, P; Testori, A; Ascierto, P; Danielli, R; DI GIACOMO, ANNA MARIA; Sileni Chiarion, V; Del Vecchio, M; Ridolfi, R; Maio, M
The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients
2009-01-01 Altomonte, M; Queirolo, P; Testori, A; Ascierto, P; Danielli, R; DI GIACOMO, ANNA MARIA; Sileni Chiarion, V; Del Vecchio, M; Ridolfi, R; Maio, M
The italian network for cancer bioimmunotherapy (NIBIT): A model to break the barriers to biological therapy of cancer
2006-01-01 Maio, M; Ascierto, P; Belardelli, F; Queirolo, P; Russo, V; Testori, S; Parmiani, G
The Italian Network for Tumor Biotherapy (NIBIT)-M1 study: 2-years survival update for metastatic melanoma patients treated with ipilimumab in combination with fotemustine
2013-01-01 Di Giacomo, Am; Ascierto, Pa; Queirolo, P; Pilla, L; Ridolfi, R; Santinami, M; Testori, A; Giannarelli, D; Parmiani, G; Maio, M
| Titolo | Data di pubblicazione | Autore(i) | File | Abstract |
|---|---|---|---|---|
| Promoter methylation controls the intratumoral heterogeneity of Cancer/Testis antigens expression in human cutaneous melanoma: Immunotherapeutic implications of epigenetic drugs | 1-gen-2006 | Fratta, E; Sigalotti, L; Coral, S; Covre, A; Nicolay, H; Pezzani, L; Cortini, E; Colizzi, F; Fonsatti, E; Altomonte, M; Maio, M | - | |
| Quantitative analysis of the expression of HLA-class I, -A, -A2 antigens beta(2)mu expressed on melanoma cells and autologous PBMC | 1-gen-1996 | Gasparollo, A; Marcon, G; Cattarossi, I; Cattelan, A; Altomonte, M; Maio, M | - | |
| Safety and efficacy of ipilimumab 10 mg/kg among patients with advanced melanoma from Italy enrolled in a European compassionate use program (EAP) | 1-gen-2012 | Maio, M; Queirolo, P; Testori, A; Altomonte, M; Maur, M; Bajetta, E; Ascierto, Pa; Chiarion Sileni, V; DI GIACOMO, ANNA MARIA; Ridolfi, R | - | |
| Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study. | 1-gen-2019 | DI GIACOMO, ANNA MARIA; Covre, Alessia; Finotello, Francesca; Rieder, Dietmar; Sigalotti, Luca; Giannarelli, Diana; Petitprez, Florent; Lacroix, Laetitia; Cutaia, Ornella; Fazio, Carolina; Coral, Sandra; Anichini, Andrea; Bock, Christoph; Lowder, James N.; Azab, Mohammad; Fridman, Wolf-Herman; Sautes-Fridman, Catherine; Trajanoski, Zlatko; Maio, Michele | - | |
| Specific cellular immune responses against NY-ESO-1 are associated with favorable survival of stage IV melanoma patients | 1-gen-2011 | Weide, B; Zelba, H; Derhovanessian, E; Pflugfelder, A; Schadendorf, D; de Vries, J; Maio, M; Garbe, C; Pawelec, G | - | |
| Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma | 1-gen-2013 | Maio, M; Bondarenko, I; Robert, C; Thomas, L; Garbe, C; Testori, A; Lu, H; Chin, K; Wolchok, J | - | |
| THE ITALIAN EXPERIENCE ON THE FEASIBILITY AND SAFETY OF IPILIMUMAB THERAPY IN PRETREATED METASTATIC MELANOMA PATIENTS | 1-gen-2009 | Altomonte, M; Queirolo, P; Testori, A; Ascierto, P; Danielli, R; DI GIACOMO, ANNA MARIA; Sileni Chiarion, V; Del Vecchio, M; Ridolfi, R; Maio, M | - | |
| The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients | 1-gen-2009 | Altomonte, M; Queirolo, P; Testori, A; Ascierto, P; Danielli, R; DI GIACOMO, ANNA MARIA; Sileni Chiarion, V; Del Vecchio, M; Ridolfi, R; Maio, M | - | |
| The italian network for cancer bioimmunotherapy (NIBIT): A model to break the barriers to biological therapy of cancer | 1-gen-2006 | Maio, M; Ascierto, P; Belardelli, F; Queirolo, P; Russo, V; Testori, S; Parmiani, G | - | |
| The Italian Network for Tumor Biotherapy (NIBIT)-M1 study: 2-years survival update for metastatic melanoma patients treated with ipilimumab in combination with fotemustine | 1-gen-2013 | Di Giacomo, Am; Ascierto, Pa; Queirolo, P; Pilla, L; Ridolfi, R; Santinami, M; Testori, A; Giannarelli, D; Parmiani, G; Maio, M | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 1 Contributo su Rivista 67
- 1 Contributo su Rivista::1.5 Abstract in rivista 67
Data di pubblicazione
- 2010 - 2020 28
- 2000 - 2009 31
- 1995 - 1999 8
Rivista
- ANNALS OF ONCOLOGY 15
- JOURNAL OF CLINICAL ONCOLOGY 11
- EUROPEAN JOURNAL OF CANCER 7
- EUROPEAN JOURNAL OF CANCER. SUPPLEMENT 7
- JOURNAL OF IMMUNOTHERAPY 5
- CELLULAR ONCOLOGY 3
- HUMAN IMMUNOLOGY 3
- JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT 3
- ASIA PACIFIC JOURNAL OF CLINICAL ONCOLOGY 2
- JOURNAL OF CLINICAL ONCOLOGY 2
Keyword
- ipilimumab 3
- melanoma 2
- brain metastases 1
- fotemustine 1
- guadecitabina 1
- guadecitabine 1
- nivolumab 1
Lingua
- eng 41
Accesso al fulltext
- no fulltext 60
- reserved 4
- open 3
Appartenenza
- Dipartimento di Biotecnologie Mediche 4
- Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze 67